Search

EHA Congratulates EHA Research Grants 2022 Recipients

May 30 2022 Posted in Press releases

The Hague, May 30, 2022 – EHA congratulates eight talented researchers in hematology on their receipt of the EHA Research Grants 2022 after a rigorous selection process.

EHA & ERN-EuroBloodNet Spotlight on Hypereosinophilic Syndrome Webinars

An accredited European online educational program for health professionals, organized by EHA and ERN-EuroBloodNet. DatesThe sessions will take place on :

Monday, April 15, 2024 at 17:00 (CEST). Monday, May 13, 2024 at 17:00 (CEST).

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

Nov 18 2020

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Publications

The EBMT/EHA CAR-T Cell Handbook
Editors: Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele. 2022, ISBN 978-3-030-94352-3 ISBN 978-3-030-94353-0 (eBook).

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Mar 27 2013 Posted in Press releases

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.